HK1061349A1 - Stabilized formulations of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxyÜphenoxy)-2-(4-methoxyphenyl) benzo ÄBÜthiophene and salts thereof - Google Patents
Stabilized formulations of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxyÜphenoxy)-2-(4-methoxyphenyl) benzo ÄBÜthiophene and salts thereofInfo
- Publication number
- HK1061349A1 HK1061349A1 HK04102381A HK04102381A HK1061349A1 HK 1061349 A1 HK1061349 A1 HK 1061349A1 HK 04102381 A HK04102381 A HK 04102381A HK 04102381 A HK04102381 A HK 04102381A HK 1061349 A1 HK1061349 A1 HK 1061349A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- piperidin
- benzo
- methoxyphenyl
- hydroxy
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20323500P | 2000-05-08 | 2000-05-08 | |
PCT/US2001/011736 WO2001085147A2 (en) | 2000-05-08 | 2001-04-30 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1061349A1 true HK1061349A1 (en) | 2004-09-17 |
Family
ID=22753086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04102381A HK1061349A1 (en) | 2000-05-08 | 2004-03-31 | Stabilized formulations of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxyÜphenoxy)-2-(4-methoxyphenyl) benzo ÄBÜthiophene and salts thereof |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1357903B1 (pl) |
JP (1) | JP2003535827A (pl) |
KR (1) | KR100806992B1 (pl) |
CN (1) | CN1283250C (pl) |
AR (1) | AR028401A1 (pl) |
AT (1) | ATE348605T1 (pl) |
AU (2) | AU5531001A (pl) |
BR (1) | BR0110620A (pl) |
CA (2) | CA2691739A1 (pl) |
CZ (1) | CZ20023651A3 (pl) |
DE (1) | DE60125416T2 (pl) |
DZ (1) | DZ3376A1 (pl) |
EA (1) | EA004871B1 (pl) |
EC (1) | ECSP014066A (pl) |
EG (1) | EG24223A (pl) |
ES (1) | ES2276784T3 (pl) |
HK (1) | HK1061349A1 (pl) |
HR (1) | HRP20020883A2 (pl) |
HU (1) | HUP0302190A3 (pl) |
IL (2) | IL152699A0 (pl) |
MX (1) | MXPA02010923A (pl) |
NO (1) | NO20025219D0 (pl) |
NZ (1) | NZ521393A (pl) |
PE (1) | PE20011255A1 (pl) |
PL (1) | PL365472A1 (pl) |
SK (1) | SK286346B6 (pl) |
SV (1) | SV2002000435A (pl) |
TW (1) | TWI225787B (pl) |
UA (1) | UA77941C2 (pl) |
WO (1) | WO2001085147A2 (pl) |
ZA (1) | ZA200207651B (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
CA2539799A1 (en) * | 2003-09-22 | 2005-03-31 | Nisshin Kyorin Pharmaceutical Co., Ltd. | 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same |
WO2016024369A1 (ja) * | 2014-08-13 | 2016-02-18 | テバ製薬株式会社 | がん治療用医薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL132952A (en) * | 1995-02-28 | 2002-02-10 | Lilly Co Eli | Derivatives of benzothiophene |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
WO2001009115A2 (en) * | 1999-07-29 | 2001-02-08 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
ZA200003837B (en) * | 1999-07-29 | 2002-01-28 | Lilly Co Eli | A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. |
WO2001009116A2 (en) * | 1999-07-29 | 2001-02-08 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
-
2001
- 2001-04-30 IL IL15269901A patent/IL152699A0/xx unknown
- 2001-04-30 DZ DZ013376A patent/DZ3376A1/xx active
- 2001-04-30 ES ES01928454T patent/ES2276784T3/es not_active Expired - Lifetime
- 2001-04-30 BR BR0110620-1A patent/BR0110620A/pt not_active Application Discontinuation
- 2001-04-30 SK SK1565-2002A patent/SK286346B6/sk not_active IP Right Cessation
- 2001-04-30 AT AT01928454T patent/ATE348605T1/de not_active IP Right Cessation
- 2001-04-30 EP EP01928454A patent/EP1357903B1/en not_active Expired - Lifetime
- 2001-04-30 UA UA2002118788A patent/UA77941C2/uk unknown
- 2001-04-30 CN CNB018091296A patent/CN1283250C/zh not_active Expired - Fee Related
- 2001-04-30 DE DE60125416T patent/DE60125416T2/de not_active Expired - Fee Related
- 2001-04-30 EA EA200201186A patent/EA004871B1/ru not_active IP Right Cessation
- 2001-04-30 HU HU0302190A patent/HUP0302190A3/hu unknown
- 2001-04-30 MX MXPA02010923A patent/MXPA02010923A/es active IP Right Grant
- 2001-04-30 KR KR1020027014923A patent/KR100806992B1/ko not_active IP Right Cessation
- 2001-04-30 PL PL01365472A patent/PL365472A1/pl not_active Application Discontinuation
- 2001-04-30 CZ CZ20023651A patent/CZ20023651A3/cs unknown
- 2001-04-30 WO PCT/US2001/011736 patent/WO2001085147A2/en active IP Right Grant
- 2001-04-30 CA CA002691739A patent/CA2691739A1/en not_active Abandoned
- 2001-04-30 CA CA002408563A patent/CA2408563A1/en not_active Abandoned
- 2001-04-30 JP JP2001581801A patent/JP2003535827A/ja active Pending
- 2001-04-30 AU AU5531001A patent/AU5531001A/xx active Pending
- 2001-04-30 AU AU2001255310A patent/AU2001255310C1/en not_active Ceased
- 2001-04-30 NZ NZ521393A patent/NZ521393A/en unknown
- 2001-05-02 AR ARP010102074A patent/AR028401A1/es unknown
- 2001-05-02 TW TW090110500A patent/TWI225787B/zh not_active IP Right Cessation
- 2001-05-04 PE PE2001000402A patent/PE20011255A1/es not_active Application Discontinuation
- 2001-05-05 EG EG20010461A patent/EG24223A/xx active
- 2001-05-07 SV SV2001000435A patent/SV2002000435A/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004066A patent/ECSP014066A/es unknown
-
2002
- 2002-09-23 ZA ZA200207651A patent/ZA200207651B/en unknown
- 2002-10-31 NO NO20025219A patent/NO20025219D0/no not_active Application Discontinuation
- 2002-11-07 IL IL152699A patent/IL152699A/en not_active IP Right Cessation
- 2002-11-08 HR HR20020883A patent/HRP20020883A2/hr not_active Application Discontinuation
-
2004
- 2004-03-31 HK HK04102381A patent/HK1061349A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107512T1 (el) | Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους | |
NO950297L (no) | Prolinamidderivater | |
MA26926A1 (fr) | Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation. | |
JO2239B1 (en) | Method for preparing benzothophen derivatives | |
HU9603185D0 (en) | New azolidinediones as antihyperglycemic agents | |
MY125099A (en) | Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid | |
MY135954A (en) | Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid | |
EG24223A (en) | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof | |
BR9812982A (pt) | Agente anti-reumático | |
NO933010D0 (no) | 4-((2-benzotiazolyl)metylamino)alfa-((3,4-difluorfenoksy)metyl)-1-piperidinetanol | |
ATE358128T1 (de) | Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation | |
EP1757291A3 (en) | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof | |
DK1174131T3 (da) | Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom | |
HUP0100999A2 (hu) | Citosztatikus szerek | |
DK0673913T3 (da) | Calcium-alkalimetalcitratforbindelser samt deres anvendelse som lægemidler | |
HUP0203476A2 (en) | Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same | |
WO2002022567A8 (en) | Novel thio derivatives of sordarin as antifungal agents | |
DK0925785T3 (da) | Stabiliseret farmaceutisk præparat indeholdende dopamin eller dobutamin | |
TH61673A (th) | สูตรผสมที่เพิ่มความคงตัวของ 6-ไฮดรอกซี-3-(4-[2-(พิเพอริดิน-1-อิล)เอทอกซี]ฟีนอกซี)-2-(4-เมทอกซีเฟนิล)เบนโซ[b]ไทโอฟีนและเกลือของสารดังกล่าว | |
ES2150392B1 (es) | "composiciones parenterales a base de calcitonina". |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110430 |